Which drug first? Real-World study seeks answers for Tough-to-Treat colorectal cancer
NCT ID NCT05839951
First seen Nov 12, 2025 · Last updated May 01, 2026 · Updated 22 times
Summary
This study looked at the medical records of 818 adults with advanced colorectal cancer that had spread to other parts of the body. Researchers wanted to see if the order in which patients took two approved drugs—regorafenib and TAS-102 (sometimes with bevacizumab)—affected their treatment. No new treatments or tests were given; the study simply analyzed existing data from routine care to learn more about real-world outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (MCRC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Many locations
Whippany, New Jersey, 07981, United States
Conditions
Explore the condition pages connected to this study.